Eupatilin alleviates right ventricular fibrosis in rats with pulmonary hypertension induced by monocrotaline.
Eupatilin, a natural compound, shows promise in treating pulmonary hypertension by reducing right ventricular fibrosis and improving heart function in a rat model, offering a potential new therapy for this deadly cardiovascular condition.
This study investigated the effects of Eupatilin, a flavonoid extracted from Artemisia, on pulmonary arterial hypertension (PAH) using both in vitro and in vivo models. The researchers found that Eupatilin inhibits the proliferation of pulmonary artery smooth muscle cells induced by platelet-derived growth factor-BB. In a rat model of PAH induced by monocrotaline, Eupatilin improved pulmonary blood flow and right ventricular function, and alleviated pulmonary artery remodeling and myocardial fibrosis. Mechanistically, Eupatilin was shown to inhibit the JNK/p38 MAPK signaling pathway. These findings suggest that Eupatilin could be a promising therapeutic candidate for the treatment of PAH, though further research is needed to fully understand its mechanisms and potential clinical applications.